重组人膜联蛋白A6(Annexin A6)

特别提示：包括重组人膜联蛋白A6(Annexin A6)在内，本公司的所有产品仅可用于科研实验，严禁用于临床医疗及其他非科研用途！

产品名称：重组人膜联蛋白A6(Annexin A6)
英文名称：Recombinant Human Annexin A6
产品货号：JN1982
产品规格：10μg|50μg|500μg|1mg

本品由我们的大肠杆菌表达系统制备而成，目的基因编码的Ala2-Asp673在C端含有His标签。

Annexin A6质量控制：＞95%(还原性SDS-PAGE)

Annexin A6制剂：冻干品

Annexin A6保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。

Annexin A6复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100 μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。

关于Annexin A6：
Annexin A6 (ANAX6) belongs to a family of calcium-dependent membrane and phospholipid binding proteins. Annexin A6 is a secreted protein and locates on the cell surface. Annexin A6 contains 8 annexin repeats separated by linking sequences of variable lengths. A pair of annexin repeats may form one binding site for calcium and phospholipid. ANXA6 is involved in the regulation of the release of Ca2+ from intracellular stores and may be associated with CD21. In addition, ANXA6 has been implicated in mediating the endosome aggregation and vesicle fusion in secreting epithelia during exocytosis.

除了重组人膜联蛋白A6(Annexin A6),，我公司还供应以下相关产品：



名称：重组人LR3-IGF1
货号：JN0227
规格：10μg|50μg|500μg|1mg
本品由我们的大肠杆菌表达系统制备，目的基因编码的Gly49-Ala118表达纯化而来。

LR3-IGF-1质量控制：＞95%(还原性SDS-PAGE)。

LR3-IGF-1制剂：冻干品

LR3-IGF-1保存：
冻干蛋白可在-20℃长期保存，室温也可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天。
复溶后建议分装冻存在-20℃，可保存3个月，应避免反复冻融。

LR3-IGF-1复溶：
1、试剂开盖前请先离心。
2、复溶浓度应大于100 μg/ml.
3、冻干蛋白溶于ddH2O中
4、复溶后根据使用量分装保存，避免反复冻融。

关于LR3-IGF-1：
Insulin-like growth factor I (IGF1) belongs to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGFs are generated by proteolytic processing of inactive precursor proteins, which contains the N- and C-terminal propeptide regions. Mature human IGF-I consisting of 70 amino acids has 94% identity with mouse IGF-I and exhibits cross-species activity. IGF-1 binds IGF-IR, IGF-IIR, and the insulin receptor and plays a key role in cell cycle progression, cell proliferation and tumor progression. IGF-1 expression is regulated by growth hormone. R3 IGF-1 is an 83 amino acid analog of IGF-1 comprising the complete human IGF-1 sequence with the substitution of an Arg (R) for the Glu(E) at position three, hence R3, and a 13 amino acid extension peptide at the N terminus. R3 IGF-1 has been produced with the purpose of increasing biological activity. R3 IGF-1 is significantly more potent than human IGF-I in vitro.